Johnson & Johnson Lifts 2025 Outlook
Johnson Johnson (NYSE:JNJ) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust operational momentum across innovative medicine and medtech.
The following insights examine how strategic execution, diversified growth drivers, and pipeline achievements are shaping the company's long-term investment profile.
Despite a 43.2% year-over-year revenue decline for Stelara from biosimilar competition, innovative medicine sales rose 3.8% operationally, with 13 brands achieving double-digit percentage growth, and medtech delivered 6.1% operational sales growth, led by a 22% surge in cardiovascular segment sales. The Stelara loss of exclusivity reduced top-line growth by approximately 710 basis points, yet U.S. pharmaceutical sales rose 7.6%, evidencing significant resilience across diversified revenue streams.
Source Fool.com
